ESE is grateful to Crinetics Pharmaceuticals
for being a Silver Sponsor of ECE 2026
Please visit them at exhibit booth 17
Satellite symposium
Monday 11 May 2026, 16:00-17:00 CEST, South Hall 2
Redefining Acromegaly Treatment
Chair: Martin Reincke, Germany
- Welcome to the future of endocrine care, Martin Reincke (Germany)
- From bench to bedside: Paltusotine - A novel therapy for Acromegaly, Beverly Biller (USA) and Christian Strasburger (Germany)
- When to use Paltusotine in the treatment of Acromegaly, Shlomo Melmed (USA)
- Roundtable discussion & questions All faculty
- Closing reflections & key takeaways, Martin Reincke (Germany)
Abstracts at ECE 2026
Poster
Impact of Stringent IGF-I Control on Glycemic Outcomes in Acromegaly: A Real-World Evidence Study in the United States (Wang et al)
Patients who achieved stringent IGF-I control experienced greater reductions in HbA1c and a higher likelihood of glycemic control in diabetes. These findings support the implementation of more stringent IGF-I targets to improve glycemic control in patients with acromegaly
Presenting Author: Rafaella Colzani
Meet the presenter and find out more during the dedicated poster viewing sessions on Sunday 10 May (16:55-17:40 CEST) and Monday 11 May (17:00-17:40 CEST).
ePoster
Study Design of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (CALM-CAH) to Evaluate Atumelnant in Adult Patients With Congenital Adrenal Hyperplasia (N Reisch et al)
This global Phase 3 trial, currently enrolling participants, will evaluate efficacy and safety of atumelnant in patients with CAH. These results will determine if atumelnant’s novel mechanism of action at the adrenal gland allows for clinically meaningful GC reductions without compromising androgen control, providing critical insight into patient benefits and risks.
ePoster
The Effect of Hepatic Impairment on the Pharmacokinetics of Atumelnant for the Treatment of Congenital Adrenal Hyperplasia and Adrenocorticotropic Hormone-Dependent Cushing Syndrome (X Wang et al)
Hepatic impairment did not result in clinically meaningful changes in the total or unbound atumelnant exposures; therefore, dose adjustment of atumelnant is not required in participants with mild, moderate, or severe hepatic impairment. A single 10-mg dose was well tolerated in participants with varying degrees of hepatic impairment.
ePoster
Absorption, Metabolism, Excretion, and Absolute Bioavailability of [14C]-Labeled Atumelnant for Treatment of Congenital Adrenal Hyperplasia and Adrenocorticotropic Hormone-Dependent Cushing Syndrome (X Wang et al)
Atumelnant has suitable PK properties for chronic once-daily oral treatment of patients with CAH and patients with ADCS.